APOE genotype predicts when — not whether — one is predisposed to develop Alzheimer disease (original) (raw)

Nature Genetics volume 19, pages 321–322 (1998)Cite this article

In an elderly population of 4,932 that included 694 subjects aged 85 and older, we studied the occurrence of Alzheimer disease (AD) in relation to APOE genotype1,2. APOE has three alleles, ε2, ε3 and ε4 — the latter of which has been associated with an increased age-specific risk of AD (ref. 1). We screened all subjects for cognitive dysfunction using either the modified mini-mental state examination3 (3MS) or a structured questionnaire4. A weighted random sample of 878 subjects was then studied with both the dementia questionnaire5 (DQ) and a detailed follow-up clinical assessment6 (CA). We investigated the remaining 4,054 with the DQ and CA when their prior results suggested cognitive impairment. A physician (D.C.S. or J.C.S.B.) reviewed the results and examined most subjects with apparent dementia. Medical records and laboratory studies (including neuroimaging) were sought, and a consensus panel of geropsychiatrists, neurologists and neuropsychologists then made final diagnoses and assigned onset ages, defined as the year subjects unambiguously met DSM-III-R criteria for dementia. Onset ages were believed accurate to within a year in most cases. We found 322 demented individuals, 220 with definite, probable or possible AD (ref. 7). In 25 autopsied cases, 17 of 18 clinical diagnoses of probable or possible AD (94.4%) were confirmed neuropathologically. Four of the five other subjects with AD neuropathology had been categorized clinically as, "dementia, undetermined aetiology," which retains AD in the differential diagnosis.

We identified all subjects who were not demented five years before their last observation and then estimated five-year disease-free survival using the Kaplan Meier product-limit method8. Analyses were limited to the last five years to curtail bias from excess mortality in late dementia. In a separate investigation, we observed an age-standardized mortality ratio of 0.82 (n.s.) in the first five years after AD onset. Details of the analyses and adjustment procedures, and their rationale, are available at http://www.mh.jhsph/survival.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. Roses, A.D. Am. J. Med. Genet. 81, 49–57 ( 1998).
    Article CAS Google Scholar
  2. Saunders, A.M. et al. Neurology 43, 1467–1472 (1993).
    Article CAS Google Scholar
  3. Teng, E.L. & Chui, H.C. J. Clin. Psychiatry 48 , 314–318 (1987).
    CAS PubMed Google Scholar
  4. Jorm, A.F. & Jacomb, P.A. Psychol. Med. 19, 1015–1022 (1989).
    Article CAS Google Scholar
  5. Silverman, J.M., Breitner, J.C.S., Mohs, R.C. & Davis, K.L. Am. J. Psychiatry 143, 1279–1282 (1986).
    Article CAS Google Scholar
  6. Breitner, J.C.S. et al. Arch. Neurol. 52, 763–771 (1995).
    Article CAS Google Scholar
  7. McKhann, G. et al. Neurology 34, 939–944 ( 1984).
    Article CAS Google Scholar
  8. Kaplan, B.L. & Meier, P. J.A.S.A. 53, 457–481 (1958).
    Article Google Scholar
  9. Norton, M.C., Breitner, J.C.S., Welsh, K.A. & Wyse, B.W. J. Am. Geriatr. Soc. 42, 1252–1256 ( 1994).
    Article CAS Google Scholar
  10. Morris, J.C. et al. Neurology 46, 707–719 ( 1996).
    Article CAS Google Scholar

Download references

Acknowledgements

We thank the Neurogenetics Laboratory of the Bryan Alzheimer Disease Research Center at Duke University for determining the APOE genotypes from buccal material. J. Anthony and R. Brookmeyer provided helpful discussions on methods. We thank G. Einstein for her helpful critique of the manuscript.

Author information

Authors and Affiliations

  1. Department of Mental Hygiene, The Johns Hopkins University, 624 North Broadway, Baltimore, 21205, Maryland, USA
    Marion R Meyer & John C S Breitner
  2. College of Family Life, Utah State University, Logan, Utah, USA
    JoAnn T Tschanz, Maria C Norton & Bonita W Wyse
  3. Department of Psychiatry and Behavioral Sciences, Duke University, Durham, North Carolina, USA
    Kathleen A Welsh-Bohmer, David C Steffens & John C S Breitner
  4. The Joseph and Kathleen Bryan Alzheimers Disease Research Center, Duke University, Durham, North Carolina, USA
    Kathleen A Welsh-Bohmer & John C S Breitner

Authors

  1. Marion R Meyer
    You can also search for this author inPubMed Google Scholar
  2. JoAnn T Tschanz
    You can also search for this author inPubMed Google Scholar
  3. Maria C Norton
    You can also search for this author inPubMed Google Scholar
  4. Kathleen A Welsh-Bohmer
    You can also search for this author inPubMed Google Scholar
  5. David C Steffens
    You can also search for this author inPubMed Google Scholar
  6. Bonita W Wyse
    You can also search for this author inPubMed Google Scholar
  7. John C S Breitner
    You can also search for this author inPubMed Google Scholar

Rights and permissions

About this article

Cite this article

Meyer, M., Tschanz, J., Norton, M. et al. APOE genotype predicts when — not whether — one is predisposed to develop Alzheimer disease.Nat Genet 19, 321–322 (1998). https://doi.org/10.1038/1206

Download citation

This article is cited by